We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+22.67%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$121M
Cap. Flow
+$49.7M
Cap. Flow %
11.29%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$49.8M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$37.1K

Sector Composition

Rank Sector Weight
1 Healthcare 60.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$136M 30.93%
8,930,237
– –
SLDB icon
2
Solid Biosciences
SLDB
$900M
$93.9M 21.3%
132,630
– –
APTX
3
DELISTED
Aptinyx Inc. Common Stock
APTX
$64.4M 14.62%
2,225,092
– –
IFRX icon
4
InflaRx
IFRX
$271M
$60.6M 13.75%
1,764,888
-1,150
-0.1% -$37.1K
REPL icon
5
Replimune Group
REPL
$1.01B
$45.7M 10.37%
+2,838,968
New +$49.8M
MRNS
6
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$39.8M 9.03%
994,363
– –

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2018 Portfolio in Review

As of Q3 2018, Bain Capital Life Sciences Investors held 6 positions worth $441M, up 38% from $319M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Bain Capital Life Sciences Investors deployed $49.7M of net new capital in Q3 2018, opening 1 new position. Its largest new stake was Replimune Group: 2,838,968 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 57% a quarter earlier.

On the sell side, the largest reduction was InflaRx, an estimated $37.1K trimmed.

  • Bain Capital Life Sciences Investors's largest Q3 2018 buy was Replimune Group: 2,838,968 shares worth $45.7M.
  • Bain Capital Life Sciences Investors's biggest Q3 2018 reduction was InflaRx, cutting an estimated $37.1K.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $441M portfolio in Q3 2018.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 0 in Q3 2018.
  • Bain Capital Life Sciences Investors's portfolio value rose 38% quarter-over-quarter to $441M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2018, filed 14 Nov 2018.